SCHEMBL2371565

SCHEMBL2371565

COc1ccc(Oc2ccc(Br)cc2C(=O)O)c(F)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.49
HTT P42858 2/20 0.47
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.45
HSD17B10 Q99714 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GFER P55789 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MYC P01106 1/20 0.44
NR4A1 P22736 1/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.44
RAB9A P51151 1/20 0.44
HPGD P15428 1/20 0.44
GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2372193 0.84 KDM4E (0.42) POLBKDM4EALDH1A1MYCNR4A1
SCHEMBL1221627 0.84 POLB (0.63) POLBHTTLCKFYNKDM4E
SCHEMBL30362007 0.84 POLB (0.63) POLBHTTLCKFYNKDM4E
Hydrochloric Acid SCHEMBL27134662 0.82 POLB (0.61) POLBLCKFYNKDM4EALDH1A1
SCHEMBL2369905 0.81 KDM4E (0.56) POLBHTTKDM4EALDH1A1MAPT
SCHEMBL2372069 0.78 LMNA (0.48) POLBHTTKDM4EALDH1A1MAPT
SCHEMBL14097990 0.78 KDM4E (0.63) POLBHTTLCKFYNKDM4E
SCHEMBL21327604 0.77 HTT (0.50) POLBHTTLCKFYNKDM4E
SCHEMBL1961466 0.77 MAPT (0.55) POLBHTTLCKFYNKDM4E
SCHEMBL30345360 0.76 HSD17B10 (0.54) POLBHTTLCKFYNKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP POLB 3640/4885HTT 2520/4885LCK 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.